HOPKINTON, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced that they will host a conference call on Thursday, August 14th, 2008 at 9:00am EDT to review the second quarter ending June 30, 2008 and discuss other matters related to the Company.
To access the conference call, please dial 877-879-6201 for domestic and 719-325-4816 international. The code for this conference call is 4315502. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, August 28th, 2008.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of
therapeutic and diagnostic products primarily for disorders in the central
nervous system (CNS). The Company maintains a world-class intellectual
property position in the field of regenerative therapeutics. The Company's
focus is reflected in several important initiatives. Cethrin, a
recombinant- protein-based drug designed to promote nerve repair after
acute spinal cord injury, demonstrated positive interim results in a Phase
I/IIa clinical trial. The Company's research and pre-clinical programs
include, Inosine for the treatment of spinal cord injury and stroke,
Oncomodulin for the treatment of ocular injury and disease and research
programs directed at a number of regenerative therapies including b
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved